At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
Zacks.com on MSN13d
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
KLBK Lubbock on MSN12d
FTC report highlights prescription drug pricing issues in LubbockPrescription drug prices are rising, and a new report from the Federal Trade Commission (FTC) explains why. Pharmacy benefit ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback